Daxor (FRA:DX5) 3-Month Share Buyback Ratio: 0.00% (As of Dec. 2025 )

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:DX5 Daxor Corp FRA:DX5
51 GF Score
Price €7.90
GF Value €29.07
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is Daxor 3-Month Share Buyback Ratio?

Daxor FRA:DX5 -3.66% 51 3-Month Share Buyback Ratio is 0.00 as of Dec. 2025. GuruFocus rates FRA:DX5 with a GF Score™ of 51/100 and a GF Value™ of €29.07 (Possible Value Trap). The stock has 1 warning sign investors should review.

3-Month Share Buyback Ratio only apply to companies whose reporting frequency is 3 months.

FRA:DX5
51GF Score
Daxor Corp FRA:DX5
3-Month Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a 3-Month Share Buyback Ratio of 0.00 mean?
Daxor (FRA:DX5) has a 3-Month Share Buyback Ratio of 0.00 as of Dec. 2025. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Daxor and its competitors.
Is Daxor's 3-Month Share Buyback Ratio too high?
Daxor's current 3-Month Share Buyback Ratio is 0.00. Overall, Daxor has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Daxor's 3-Month Share Buyback Ratio compare to POCI and NEPH?
Daxor's 3-Month Share Buyback Ratio of 0.00 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Month Share Buyback Ratio for a Medical Devices & Instruments company?
A good 3-Month Share Buyback Ratio depends on the Medical Devices & Instruments industry context. However, 3-Month Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Month Share Buyback Ratio mean?
A high 3-Month Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Daxor and its competitors. Daxor's current 3-Month Share Buyback Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Daxor stock overvalued right now?
Based on GuruFocus' analysis, Daxor (FRA:DX5) is currently considered Possible Value Trap. The stock's GF Value™ is €29.07, compared to a current price of €7.90 — trading 72.8% below its estimated fair value. The current 3-Month Share Buyback Ratio is 0.00. Daxor's overall GF Score™ is 51/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Month Share Buyback Ratio calculated?
3-Month Share Buyback Ratio is calculated from a company's financial statements. For Daxor (FRA:DX5), the current 3-Month Share Buyback Ratio is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Daxor (FRA:DX5) Overvalued in 2026?

Based on GuruFocus' analysis, Daxor stock appears to be undervalued. The current stock price of €7.90 is trading 72.8% below its estimated GF Value™ of €29.07. GuruFocus considers Daxor to be Possible Value Trap.

Key valuation signals for FRA:DX5:

  • 3-Month Share Buyback Ratio: 0.00
  • GF Value™: €29.07 vs. price of €7.90 (72.8% below fair value)
  • GF Score™: 51/100 with 1 warning sign

No single metric tells the full story. See the FRA:DX5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Daxor Business Description

Other Exchanges DXR:USA
Address 107 Meco Lane, Oak Ridge, TN, USA, 37830
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system.
51GF Score

Get the complete analysis for FRA:DX5

3-Month Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.90
Price
€29.07
GF Value